Cap­si­da and Ab­b­Vie make $70M up­front deal for ge­net­ic med­i­cines in eye dis­eases

Ab­b­Vie is ex­pand­ing its part­ner­ship with gene ther­a­py de­vel­op­er Cap­si­da in a deal to de­vel­op ge­net­ic ther­a­pies for eye dis­eases.

The deal comes with a $70 mil­lion up­front pay­ment, as much as $595 mil­lion in mile­stone pay­ments, and pos­si­ble com­mer­cial pay­ments, ac­cord­ing to a state­ment from the com­pa­nies. Un­der the deal, they will iden­ti­fy and de­vel­op as many as three pro­grams.

The deal is an ex­pan­sion of Ab­b­Vie and Cap­si­da’s 2021 part­ner­ship, in which Ab­b­Vie made a $90 mil­lion up­front pay­ment and the com­pa­nies agreed to work on cen­tral ner­vous sys­tem dis­eases. And in Jan­u­ary, Cap­si­da an­nounced a part­ner­ship with Eli Lil­ly, tak­ing in $55 mil­lion in up­front pay­ments plus mile­stones to de­vel­op gene ther­a­pies for cen­tral ner­vous sys­tem dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER